FCGR2A and COVID-19: Interestingly, CD32/FcγRII inhibition enhanced both type-I IFN and IL-6 responses compared to complement induction alone, which might be due to higher complement concentrations in serum from severe COVID-19 patients as suggested by higher opsonization of SARS-CoV-2 (Fig. 6A).